Introduction
============

Inherited retinal dystrophies (IRDs) are a group of disorders characterized by progressive dysfunction of photoreceptors and vision loss. Despite clinical and genetic heterogeneities, IRDs are mostly monogenic diseases. Retinitis pigmentosa (RP; MIM: 268,000), the most common form of IRDs, is characterized by primary dysfunctions of the rod photoreceptors followed by degeneration of the RPE and cone photoreceptors \[[@r1]\]. Clinical hallmarks of RP include night blindness, progressive visual field (VF) constrictions, and final loss of central vision. In genetic aspects, RP is a monogenic disease that can be inherited via all three Mendelian inheritance modes, including autosomal dominant, autosomal recessive, and X-linked patterns \[[@r2]\]. Digenic traits have also been reported \[[@r3],[@r4]\]. To date, 82 RP causative genes and 89 RP-associated loci have been reported. The remarkable genetic heterogeneity calls for an efficient and high throughput technique to assist the molecular diagnosis of RP. Next-generation sequencing (NGS) is capable of detecting mutations with high efficiency and precision, and has therefore been considered the most efficient approach for mutation screening \[[@r5],[@r6]\].

The *eyes shut homolog* (*EYS*; OMIM: [612424](http://omim.org/entry/612424)) gene, located on chromosome 6p12 and spanning 2 Mb, is the largest eye-specific gene identified by far \[[@r7],[@r8]\]. The protein eyes shut homolog, the protein encoded by the *EYS* gene, is a 3,165-amino-acid protein that contains five laminin G-like domains and 27 epidermal growth factor (EGF)-like domains. This protein shows exclusive expression in the outer segments of photoreceptors and functions in the visual perception process \[[@r8]\]. Mutations in the *EYS* gene are among the most prominent causes of RP and even some other types of IRDs \[[@r9]-[@r11]\]. Herein, with a targeted NGS approach, we reveal five *EYS* mutations as disease causative in four Chinese families with RP. The genotypic-phenotypic correlations in all Chinese patients carrying mutations in the *EYS* gene are reviewed and discussed.

Methods
=======

Participants and clinical evaluations
-------------------------------------

This study, designed in accordance with the tenets of the Declaration of Helsinki and adhered to the ARVO statement on human subjects, was approved by the Ethics Committee on Human Research of Nanjing Medical University. Written informed consent was obtained from all participants before participation. Four patients with IRDs and seven unaffected family members from four individual families were recruited from the First Affiliated Hospital of Nanjing Medical University ([Figure 1A](#f1){ref-type="fig"}). All participants received routine ophthalmic examinations, including assessments of best-corrected visual acuity (BCVA; Snellen), slit-lamp examinations, funduscope, and VF measurements. Comprehensive ophthalmic tests, including an electroretinogram (ERG) test, optical coherence tomography (OCT) examination, and fundus fluorescein angiography (FFA), were performed on the two included patients. Additionally, 100 unrelated Chinese controls with neither major ocular diseases as demonstrated with routine ophthalmic examinations nor family history of any type of IRD were included in the study for prevalence tests. Peripheral blood samples were collected in EDTA tubes. DNA extraction from leukocytes was performed using a QIAmp DNA blood kit (Qiagen, Valencia, CA) according to the manufacturer's protocols.

![Family pedigrees and identified *EYS* variations. **A**: Pedigrees of families ARRP07, ARRP08, ARRP09, and ARRP10 are demonstrated. *EYS* genotypes for all included family members are demonstrated under their symbols. Probands are indicated by arrows. Circles represent females, and squares, males. Filled symbols represent patients, and empty symbols, controls. **B**--**G**: DNA chromatograms of all mutant sequences and the corresponding wild-type sequences.](mv-v22-646-f1){#f1}

Targeted NGS approach, bioinformatics analyses, and Sanger sequencing
---------------------------------------------------------------------

A targeted NGS approach was selectively conducted on probands from the four individual families, ARRP07-II:1, ARRP08-II:2, ARRP09-II:1 and ARRP10-II:3, using a custom-designed in-solution capture array targeting 205 reported retinal disease-associated genes and 15 candidate genes. Candidate genes were included based on publications and our previous work. Details of the 220 selected genes are provided in Appendix 1. This capture array targeted the coding sequences, 100 bp flanking regions, and 5′- and 3′-untranslated regions (UTR) of each selected gene. A total of 40 samples, including the four probands' samples, were multiplexed in the Illumina HiSeq2000 platform (Illumina, Inc., San Diego, CA). Library preparation, qualification, and NGS on the Illumina HiSeq2000 platform were performed as described previously \[[@r12]-[@r16]\]. Briefly, 6 μg of the patients' DNA samples was randomly fragmented into 250 to 300 bp segments. The fragments were then ligated with adaptors and amplified via ligation-mediated polymerase chain reaction (LM-PCR) \[[@r17]\]. DNA was then purified and hybridized for enrichment. Quantitative PCR was then performed on non-captured and captured LM-PCR products to estimate the magnitude of enrichment. Sequence reads were then aligned to the reference human genome 19 (hg19) for annotations of single nucleotide variations (SNVs) together with insertions and deletions (indel). The annotated variants were then filtered against six single nucleotide polymorphism (SNP) databases, including [dbSNP144](http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/snp144.txt.gz.), [HapMap](ftp://ftp.ncbi.nlm.nih.gov/hapmap) project, [1000 Genome](ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp) Project, [YH database](http://yh.genomics.org.cn/), [Exome Variant Server](http://evs.gs.washington.edu/EVS/) (EVS), and [Exome Aggregation Consortium](http://exac.broadinstitute.org) (EXAC). Sanger sequencing was used for mutation verification and prevalence testing according to a previously defined protocol \[[@r18]\]. Primer information is provided in Appendix 2.

In silico analyses
------------------

SWISS-MODEL online server was applied to construct the crystal structural models of the wild-type and mutant proteins \[[@r19],[@r20]\]. Predicted structures were visualized and compared using PyMol software (version 1.5). Potential pathogenicity of the identified mutations was evaluated using three types of online predictive software, including Sorting Intolerant From Tolerant ([SIFT](http://sift.jcvi.org/)) \[[@r21]\], polymorphism phenotyping v2 ([PolyPhene-2](http://genetics.bwh.harvard.edu/pph2/)) \[[@r22]\], and Protein Variation Effect Analyzer ([PROVEAN](http://provean.jcvi.org/index.php)) \[[@r23]\].

Results
=======

Clinical manifestations
-----------------------

All four probands presented typical RP symptoms, including initial nyctalopia, constricted VF, and decreased visual acuities. The RP age of onset and disease progression varied greatly among different patients. ARRP07-II:1, a 33-year-old female patient, claimed to have had night blindness since age 8, the youngest disease age of onset among all investigated patients. However, her disease progressed so slowly that she did not notice VF constriction until age 24. Her current BCVA was 20/50 for the right eye and 20/40 for the left eye with her current VF less than 15° for both eyes. Patient ARRP09-II:1, aged 56, showed nyctalopia since age 20, and her disease progressed slowly. Her BCVA was 20/50 for both eyes at her last visit to our hospital. Patients ARRP08-II:2 and ARRP10-II:3 showed late RP onset but fast disease progression. Patient ARRP08-II:2, aged 40, had nyctalopia at age 35. His current BCVA was 20/40 for both eyes, and his current VF was less than 30°. ARRP10-II:3, a female patient aged 41, reported initial symptoms at age 32. Her BCVA was 20/40 for both eyes.

Ophthalmic examinations indicated typical RP fundus, including optic disc pallor, attenuated retinal arterioles, and bone spicule-like pigments in the mid-peripheral retina of patients ARRP08-II:2 and ARRP10-II:3 ([Figure 2B,D](#f2){ref-type="fig"}). No pigment deposit was observed in the fundus of patients ARRP07-II:1 or ARRP09-II:1, which helped to modify their clinical diagnoses to RP sino pigmento (RPSP; [Figure 2A,C](#f2){ref-type="fig"}). A thickened inner/outer segment (IS/OS) layer with a preserved macular structure was suggested by OCT presentations of all four recruited patients ([Figure 2F--I](#f2){ref-type="fig"}). Significantly decreased ERG presentations were also found for all included patients. No patient reported systemic defects.

![Fundus and OCT presentations. **A** and **C**: Fundus photographs of patient ARRP07-II:1 (**A**) and ARRP09-II:1 (**C**) indicate attenuated arterials and waxy optic discs without pigmentation. **B** and **D**: Typical retinitis pigmentosa (RP) presentations are revealed in the fundus of patients ARRP08-II:2 (**B**) and ARRP10-II:3 (**D**), suggesting arterial attenuation, waxy optic disc, and bone spicule-like pigmentation. **E**: Fundus of a control individual. **F**--**I**: Optical coherence tomography (OCT) presentations of patients ARRP07-II:1 (**F**), ARRP08-II:2 (**G**), ARRP09-II:1 (**H**), and ARRP10-II:3 (**I**) suggest an attenuated outer nuclear layer (ONL), RPE, and loss of outer/inner segments (IS/OS). The macular regions of all patients were relatively preserved.](mv-v22-646-f2){#f2}

Genetic findings
----------------

Targeted NGS was selectively performed on patients ARRP07-II:1, ARRP08-II:2, ARRP09-II:1, and ARRP10-II:3. The NGS results are detailed in Appendix 3. Briefly, the average coverage and depth of the targeted region reached 94.68% and 60.34-fold, respectively. A total of 8,142 variants covering 7,236 SNPs and 906 indels were revealed with the initial NGS approach in all four tested patients. The detailed process for filtration and validation is demonstrated in [Table 1](#t1){ref-type="table"}. After comprehensive genetic analyses, we confirmed six variations in the *EYS* gene ([NM_001142800](http://www.ncbi.nlm.nih.gov/nuccore/NM_001142800); [NP_001136272](http://www.ncbi.nlm.nih.gov/nuccore/NP_001136272)) that segregated the disease phenotypes within the four families. A homozygous recurrent missense mutation, c.6557G\>A, was found carried by patient ARRP07-II:1 ([Figure 1A,B](#f1){ref-type="fig"}) \[[@r10]\]. This mutation would lead to the substitution from the neutral glycine to the acidic glutamic acid at residue 2186, which was located in the second Laminin G-like domain of the protein eyes shut homolog ([Figure 3](#f3){ref-type="fig"}). All three types of online predictive software suggested the potential deleterious effect of this mutation ([Table 2](#t2){ref-type="table"}). Crystal structures of the wild-type and mutant eys proteins carrying p.G2186E were built based on template 3poy.1A as indicated previously \[[@r24]\]. This mutation was predicted to cause the generation of two hydrogen bonds between the mutated glutamic acid at residue 2186 and arginine at residue 2306 and threonine at residue 2181, respectively ([Figure 3B,C](#f3){ref-type="fig"}).

###### Variations identified in each family.

  **Items**                                                        **ARRP07**   **ARRP08**   **ARRP09**   **ARRP10**                          
  ---------------------------------------------------------------- ------------ ------------ ------------ ------------ ------ -------- ------ --------
  SNVs/Indels                                                      SNVs         Indels       SNVs         Indels       SNVs   Indels   SNVs   Indels
  Initial variants                                                 1353         159          1289         147          2548   293      2046   307
  Excluded variants found in SNP databases                         1312         149          52           135          2481   282      1979   293
  Remaining variants                                               41           9            52           12           67     11       67     14
  Excluded non-coding variants                                     34           9            43           12           60     11       58     12
  Remaining variants for Sanger sequencing                         7            0            9            0            7      0        9      2
  Excluded false positive variants                                 0            0            0            0            0      0        0      0
  Remaining variants                                               7            0            9            0            7      0        9      2
  Excluded variants failed intra-familial cosegregation analysis   7            0            6            0            5      0        8      1
  Remaining variants                                               1            0            3            0            2      0        1      1

Abbreviations: SNVs: single nucleotide variations; Indels: insertions and deletions.

![*EYS* variations identified in the present study. **A**: Schematic representation of the linear location of the identified *EYS* variants in the context of the genome (upper) and the protein (below). **B**--**E**: Crystal structural models of the wild-type (**B** and **D**) and mutant protein eyes shut homolog (**C** and **E**).](mv-v22-646-f3){#f3}

###### Characteristics of identified *EYS* mutations.

  **Family ID**   **Disease**     **Variation**   **Exon /Intron**   **Bioinformatics Analysis**   **HGMD/ Novel**                                                                  
  --------------- --------------- --------------- ------------------ ----------------------------- ----------------- ----------- ------------ ------------ ----------- ------------ ----------
  ARRP07          RPSP            6: 64,791,763   c.6557G\>A         p.G2186E                      missense          Hom         E32          DA (0.03)    PD (0.68)   DE (−2.62)   CM103598
  ARRP08          RP              6: 65,300,667   c.5093T\>C         p.I1698T                      missense          Het         E26          DA (0)       B (0.082)   N (−0.87)    VUS
  6: 64,430,679   c.9248G\>A      p.G3083D        missense           Het                           E43               DA (0.02)   DA (0.979)   N (−2.1)     Novel                    
  6: 64,940,493   c.6416G\>A      p.C2139Y        missense           Het                           E31               DA (0)      PD (0.797)   DE (−4.56)   CM102730                 
  ARRP09          RPSP            6: 64,791,763   c.6557G\>A         p.G2186E                      missense          Het         E32          DA (0.03)    PD (0.68)   DE (−2.62)   CM103598
  6: 64,574,078   c.7228+1 G\>A   p.A2410Gfs\*4   splice site        Het                           I36--37           NA          NA           NA           Novel                    
  ARRP10          RP              6: 64,574,078   c.7228+1 G\>A      p.A2410Gfs\*4                 splice site       Het         I36--37      NA           NA          NA           Novel
  6: 65,300,802   c.4957dupA      p.S1653Kfs\*2   frameshift         Het                           E26               NA          NA           NA           Novel                    

**Abbreviations:** RPSP: retinitis pigmentosa sino pigmento; RP: retinitis pigmentosa; Hom: homozygous; Het: heterozygous; DA: damaging; NA: not available; PD: probably damaging; B: benign; DE: deleterious; N: neutral; HGMD: the Human Gene Mutation Database; VUS: variant of unknown significance.

Biallelic *EYS* variants, c.\[5093T\>C; 6416G\>A\];\[9248G\>A\], were found to be carried by patient ARRP08-II:2 ([Figure 1A,C--E](#f1){ref-type="fig"}). The missense variant c.9248G\>A was novel, while c.5093T\>C was determined as a variant of unknown significance (VUS) due to its colocalization in the same allele with the reported pathogenic mutation c.6416G\>A. The missense variant c.9248G\>A would induce a change from the neutral glycine to the acidic aspartic acid at residue 3083 (p.G3083D; [Figure 1A,E](#f1){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}). The crystal structure of the mutant protein with p.G3083D indicated shortening of the neighboring β-sheet, which could alter its tertiary structure and physicochemical properties ([Figure 3D,E](#f3){ref-type="fig"}). The recurrent mutation c.6416G\>A would lead to an amino acid change from the hydrophilic cysteine to the hydrophobic tyrosine at residue 2139 (p.C2139Y). Our previous work revealed the generation of a novel hydrogen bond and vanishing of the original twist led by this mutation \[[@r24]\]. The VUS c.5093T\>C would lead to the substitution from the hydrophobic isoleucine to the hydrophilic threonine at residue 1698 (p.I1698T).

Similar to patient ARRP08-II:2, biallelic *EYS* mutations, c.\[6557G\>A\];\[7228+1G\>A\], were found to be carried by patient ARRP09-II:1. The missense c.6557G\>A was the same recurrent mutation carried by patient ARRP07-II:1. The novel splice-site variation c.7228+1G\>A was predicted to abolish the regular splice donor site and generate a truncated protein p.A2410Gfs\*4 or cause nonsense-mediated mRNA decay (NMD). This variation was found to be shared by patient ARRP10-II:3, who carried biallelic heterozygous c.\[4957dupA\];\[7228+1G\>A\]. The first variant was a reported frameshift variation that might generate a truncated protein p.S1653Kfs\*2 or cause NMD. The two novel variations, c.7228+1G\>A and c.9248G\>A, were further confirmed absent in the 100 unrelated healthy controls.

Discussion
==========

Mutations in the *EYS* gene play a prominent causative role in RP etiology, and their involvement in cone-rod dystrophy (CRD) has also been revealed in recent studies \[[@r25],[@r26]\]. *EYS* mutations that give rise to a panel of phenotypes with their inter- and intrafamilial phenotypic diversities been reported \[[@r8],[@r24]\]. Therefore, a clear insight into the genotypic and phenotypic spectrums for *EYS* mutations will help with better clinical management. In the present study, two novel and three recurrent *EYS* mutations, together with one VUS, were found to be RP causative for four individual families. We also for the first time report the correlation between *EYS* mutation and RPSP. The genotype and phenotype correlations in all Chinese patients carrying *EYS* mutations were reviewed and are summarized in [Table 3](#t3){ref-type="table"} \[[@r24],[@r27]-[@r29]\].

###### Genetic and clinical features of all reported Chinese RP patients.

  **Mutation**   **Patient ID**                       **Disease**                **Age (year)/ Sex**   **Onset Age (year)**   **Clinical presentation**   **Reference**                                                                        
  -------------- ------------------------------------ -------------------------- --------------------- ---------------------- --------------------------- --------------- -------- -------- --------- ------------- ------------ ------------- -------------
  1\*            \-                                   p.E1836\* (Hom)            II:1                  RP                     NA/F                        20              20/400   HM       \-        \-            Diminished   \-            \[[@r28]\]
  1\*            \-                                   p.E1836\* (Hom)            II:2                  RP                     40/M                        15              20/400   20/400   Diffuse   Mild pallor   Diminished   \-            \[[@r28]\]
  1\*            \-                                   p.E1836\* (Hom)            II:5                  RP                     NA/F                        20              20/400   HM       \-        \-            Diminished   \-            \[[@r28]\]
  1\*            c.\[8012T\>A\];\[704G\>A\]           p.\[L2671\*\];\[W235\*\]   F35--1                IRDs                   43/M                        13              20/100   20/100   \-        \-            \-           \-            \[[@r29]\]
  2^\#^          c.\[490C\>T\];\[6416G\>A\]           p.\[R614\*\];\[C2139Y\]    ARRP05-II:3           RP                     40/M                        22              FC       FC       Diffuse   Waxy          Diminished   \-            \[[@r24]\]
  2^\#^          c.\[490C\>T\];\[6416G\>A\]           p.\[R614\*\];\[C2139Y\]    ARRP05-II:5           RP                     37/M                        20              HM       HM       \-        \-            \-           \-            \[[@r24]\]
  2^\#^          c.\[490C\>T\];\[6416G\>A\]           p.\[R614\*\];\[C2139Y\]    ARRP05-II:7           RP                     32/M                        25              20/200   20/200   Diffuse   Waxy          Diminished   \-            \[[@r24]\]
  2^\#^          c.\[7919G\>A\];\[8861T\>C\]          p.\[W2640\*\];\[F2954S\]   ARRP06-II:2           RP                     54/M                        18              LP       LP       Diffuse   Waxy          Diminished   \-            \[[@r24]\]
  2^\#^          c.\[7919G\>A\];\[8861T\>C\]          p.\[W2640\*\];\[F2954S\]   ARRP06-II:4           RP                     52/M                        35              LP       LP       Diffuse   Waxy          Diminished   \-            \[[@r24]\]
  2^\#^          c.\[7919G\>A\];\[8861T\>C\]          p.\[W2640\*\];\[F2954S\]   ARRP06-II:8           RP                     49/F                        32              20/25    20/25    Diffuse   Waxy          Reduced      Constricted   \[[@r24]\]
  2^\#^          c.\[6557G\>A\]; \[9186_9187delCA\]   p.\[G2186E\];\[NA\]        W127--1               IRDs                   48/F                        20              20/100   20/500   \-        \-            \-           \-            \[[@r29]\]
  2^\#^          c.\[6416G\>A\];\[8150delA\]          p.\[C2139Y\];\[NA\]        W286--1               IRDs                   43/M                        20              FC       20/400   \-        \-            \-           \-            \[[@r29]\]
  2^\#^          c.\[2510G\>T\];\[8107G\>T\]          p.\[C837F\];\[E2703\*\]    F11--1                IRDs                   48/M                        41              20/50    20/50    \-        \-            \-           \-            \[[@r29]\]
  2^\#^          c.\[7492G\>C\]; \[8244_8245insT\]    p.\[A2498P\];\[NA\]        W82--1                IRDs                   43/F                        22              20/40    20/40    \-        \-            \-           \-            \[[@r29]\]
  2^\#^          c.\[6416G\>A\];\[8392delG\]          p.\[C2139Y\];\[NA\]        W86--1                IRDs                   25/M                        15              20/32    20/32    \-        \-            \-           \-            \[[@r29]\]
  3^\$^          c.\[6416G\>A\];\[6557G\>A\]          p.\[C2139Y\];\[G2186E\]    No.10-II:1            RP                     49/F                        42              20/30    20/30    Diffuse   Mild pallor   Diminished   Constricted   \[[@r27]\]
  3^\$^          c.\[6416G\>A\];\[6557G\>A\]          p.\[C2139Y\];\[G2186E\]    No.10-II:3            RP                     45/M                        36              20/50    20/40    Diffuse   Mild pallor   Diminished   Constricted   \[[@r27]\]
  3^\$^          c.\[6416G\>A\];\[6557G\>A\]          p.\[C2139Y\];\[G2186E\]    No.10-II:4            RP                     35/F                        20              20/30    20/30    Diffuse   Mild pallor   Diminished   Constricted   \[[@r27]\]
  3^\$^          c.\[9368A\>C\];\[6416G\>A\]          p.\[N3123T\];\[C2139Y\]    W5--1                 IRDs                   34/M                        14              20/40    20/40    \-        \-            \-           \-            \[[@r29]\]
  3^\$^          c.7492G\>C (Hom)                     p.A2498P (Hom)             W159--1               IRDs                   34/M                        20              20/40    20/50    \-        \-            \-           \-            \[[@r29]\]
  3^\$^          c.\[7609G\>A\];\[7949C\>T\]          p.\[A2537T\];\[S2650F\]    W171--1               IRDs                   37/F                        20              FC       FC       \-        \-            \-           \-            \[[@r29]\]
  3^\$^          c.\[3489T\>A\];\[2644T\>C\]          p.\[N1163K\];\[F882L\]     W13--1                IRDs                   63/M                        41              20/125   20/100   \-        \-            \-           \-            \[[@r29]\])
  3^\$^          c.6416G\>A (Hom)                     p.C2139Y (Hom)             W75--1                IRDs                   31/M                        20              20/100   20/100   \-        \-            \-           \-            \[[@r29]\]

**Abbreviations:** \* loss of function & loss of function alleles; \# loss of function & missense alleles; \$ missense & missense alleles; RP: retinitis pigmentosa; IRDs: inherited retinal degenerations; Hom: homozygous; BCVA: best corrected visual acuity; O.D.: right eye; O.S.: left eye; FC: finger count; HM: hand movement; LP: light perception; ERG: electroretinography; VF: visual field.

Two sporadic patients, including a 33-year-old female with the age of onset of 8 and a 56-year-old female with the age of onset of 20, were finalized with a clinical diagnosis of RPSP based on comprehensive ophthalmic examinations. The recurrent mutation, *EYS* p.G2186E, a mutational hotspot among multiple ethnic groups \[[@r10],[@r27],[@r30]\], was found to be carried by both patients. Crystal structural analysis suggests the generation of two abnormal hydrogen bonds caused by this mutation, which alters the tertiary structure of the protein and interrupts its physicochemical properties. In previous studies, the RP age of onset of patients carrying p.G2186E range from 14- to 62 years-old, while one patient in this study carrying a homozygous p.G2186E mutation claims to have had night blindness at age 8, younger than all reported cases. This mutation has been reported in two Chinese families, including a family with autosomal recessive retinal pigmentosa (arRP) and a sporadic case ([Table 3](#t3){ref-type="table"}) \[[@r27],[@r29]\]. The age of onset ranged from 20 to 42 and demonstrated remarkable inter-familial diversity. Diffuse pigmentations are detected in all patients from the family with arRP, while no pigmentation was found in the two cases in our study. The elder patient also carries a novel heterozygous *EYS* mutation c.7228+1 G\>A, a splice-site variant that may eliminate the regular splice site and generate a truncated protein p.A2410Gfs\*4 or cause NMD. This variant was also found to be carried by another patient with typical RP, implying correlated phenotypic diversity. To the best of our knowledge, this is the first time that an *EYS* mutation was found to be correlated with RPSP.

Another hotspot *EYS* mutation, p.C2139Y located in the EGF-like domain of the eys protein, was observed in a 40-year-old male patient with RP \[[@r26],[@r27],[@r29]\]. This patient developed RP at age 35, and the disease progressed quickly since its development. According to our summary, this is most common *EYS* mutation among the Chinese population with age of onset ranging from 14- to 42 years-old ([Table 3](#t3){ref-type="table"}). Our group has recently reported a Chinese family carrying this mutation with similar late onset and rapid progress \[[@r24]\]. This patient also carries a novel heterozygous *EYS* mutation, p.G3083D, which has been found to induce the elongation of its neighboring β-sheet, and a missense VUS c.5093T\>C colocalized in the same allele with the reported pathogenic mutation p.C2139Y. Another recurrent mutation, the frameshift c.4957dupA, was found to be carried by patient ARRP10-II:3, the same patient who carries c.7228+1G\>A. This mutation has not been previously reported in the Chinese population but is a hotspot in the Japanese population \[[@r30],[@r31]\].

In summary, with a targeted NGS approach, we reveal five *EYS* mutations as disease causative for four Chinese RP families with the genotype--phenotype correlations annotated. We also, for the first time, report the implication of *EYS* mutations in the etiology of RPSP, which extends the phenotypic spectrum for *EYS*-associated retinopathy. Genetic assessments would help with better clinical management of patients with IRDs. Taken together, our study provides novel insights into the etiology of RP, which are important for clinicians to obtain better genetic diagnosis, prognosis, and personalized treatment for patients with RP. However, the specific pathogenic mechanism underlying the phenotypic variability correlated with *EYS* mutations is currently under debate. Future investigations are still warranted.
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